Halozyme Therapeutics (NASDAQ:HALO) Announces Earnings Results

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) issued its earnings results on Tuesday. The biopharmaceutical company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.17 by $0.02, Zacks reports. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock traded up $0.31 during trading on Friday, reaching $57.75. The company had a trading volume of 1,299,523 shares, compared to its average volume of 1,313,186. Halozyme Therapeutics has a 52 week low of $37.73 and a 52 week high of $65.53. The firm's 50-day simple moving average is $53.46 and its 200 day simple moving average is $54.62. The firm has a market capitalization of $7.11 billion, a price-to-earnings ratio of 16.84, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14.

Insider Buying and Selling

In related news, Director Jeffrey William Henderson sold 10,000 shares of the firm's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now directly owns 43,611 shares of the company's stock, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have commented on HALO. Piper Sandler increased their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research note on Friday, January 10th. Benchmark reiterated a "buy" rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research note on Thursday. Wells Fargo & Company cut their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. JMP Securities raised their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a research note on Friday, November 1st. Finally, HC Wainwright raised their price target on Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a "buy" rating in a research note on Wednesday. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $62.78.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.